VVOS Stock Overview
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vivos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.66 |
| 52 Week High | US$48.79 |
| 52 Week Low | US$2.40 |
| Beta | 7.9 |
| 1 Month Change | -40.22% |
| 3 Month Change | -59.08% |
| 1 Year Change | -71.44% |
| 3 Year Change | -98.61% |
| 5 Year Change | n/a |
| Change since IPO | -98.82% |
Recent News & Updates
Recent updates
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks
Feb 02
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Apr 18Vivos Therapeutics again delays Q2 2022 results
Aug 23Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada
Jun 29Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be
May 21Vivos Therapeutics: First Take After The Broad Market Sell-Off
Mar 06Vivos Therapeutics: Reimagining Sleep
Jul 30Vivos Therapeutics prices $24M follow-on offering
May 07Shareholder Returns
| VVOS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -2.9% | 4.2% | -3.7% |
| 1Y | -71.4% | 2.5% | 20.2% |
Return vs Industry: VVOS underperformed the US Healthcare industry which returned 0.8% over the past year.
Return vs Market: VVOS underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| VVOS volatility | |
|---|---|
| VVOS Average Weekly Movement | 16.2% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VVOS's share price has been volatile over the past 3 months.
Volatility Over Time: VVOS's weekly volatility has decreased from 120% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 119 | R. Huntsman | vivos.com |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.
Vivos Therapeutics, Inc. Fundamentals Summary
| VVOS fundamental statistics | |
|---|---|
| Market cap | US$7.27m |
| Earnings (TTM) | -US$13.58m |
| Revenue (TTM) | US$13.80m |
0.5x
P/S Ratio-0.5x
P/E RatioIs VVOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVOS income statement (TTM) | |
|---|---|
| Revenue | US$13.80m |
| Cost of Revenue | US$5.53m |
| Gross Profit | US$8.27m |
| Other Expenses | US$21.85m |
| Earnings | -US$13.58m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.97 |
| Gross Margin | 59.93% |
| Net Profit Margin | -98.42% |
| Debt/Equity Ratio | 0% |
How did VVOS perform over the long term?
See historical performance and comparison